Cargando…

Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer

Precancerous lesions are the intermediate stage in the development of liver cancer from cirrhosis. Early intervention measures can effectively prevent the occurrence of liver cancer and prolong the lives of patients, resulting in greater economic effects. Erzhu Jiedu decoction (EJD) is a semiempiric...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yang, Chen, Tianyang, Chen, Jianjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646158/
https://www.ncbi.nlm.nih.gov/pubmed/33193894
http://dx.doi.org/10.7150/jca.49554
_version_ 1783606739007963136
author Cheng, Yang
Chen, Tianyang
Chen, Jianjie
author_facet Cheng, Yang
Chen, Tianyang
Chen, Jianjie
author_sort Cheng, Yang
collection PubMed
description Precancerous lesions are the intermediate stage in the development of liver cancer from cirrhosis. Early intervention measures can effectively prevent the occurrence of liver cancer and prolong the lives of patients, resulting in greater economic effects. Erzhu Jiedu decoction (EJD) is a semiempirical formula that is used in the treatment of cirrhosis and liver cancer according to the academic philosophy of “Preventive treatment of disease” and has achieved good curative effects in clinical practice. The purpose of this study was to investigate the effect of EJD on liver precancerous lesions induced by diethylnitrosamine (DEN) in rats. The results showed that EJD improved the general conditions (body weight, ALT, AST, and GGT) and reduced the number of precancerous lesions in the rat model. Notably, the medium dose of EJD (1.05 g/kg) had better treatment effects than the low dose of EJD, and the high dose of EJD did not further improve the liver lesions compared to the medium dose of EJD. Moreover, EJD effectively reduced the DEN-induced GST-Pi, AFP, CK19, c-Myc, and Ki67 protein expression in liver precancerous tissues. Interestingly, EJD significantly reduced YAP and TAZ mRNA expression in the liver precancerous lesions. Collectively, EJD protects against in the initiation of liver cancer and the regulation of c-Myc and Hippo signaling pathways may be the underlying mechanism.
format Online
Article
Text
id pubmed-7646158
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-76461582020-11-12 Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer Cheng, Yang Chen, Tianyang Chen, Jianjie J Cancer Research Paper Precancerous lesions are the intermediate stage in the development of liver cancer from cirrhosis. Early intervention measures can effectively prevent the occurrence of liver cancer and prolong the lives of patients, resulting in greater economic effects. Erzhu Jiedu decoction (EJD) is a semiempirical formula that is used in the treatment of cirrhosis and liver cancer according to the academic philosophy of “Preventive treatment of disease” and has achieved good curative effects in clinical practice. The purpose of this study was to investigate the effect of EJD on liver precancerous lesions induced by diethylnitrosamine (DEN) in rats. The results showed that EJD improved the general conditions (body weight, ALT, AST, and GGT) and reduced the number of precancerous lesions in the rat model. Notably, the medium dose of EJD (1.05 g/kg) had better treatment effects than the low dose of EJD, and the high dose of EJD did not further improve the liver lesions compared to the medium dose of EJD. Moreover, EJD effectively reduced the DEN-induced GST-Pi, AFP, CK19, c-Myc, and Ki67 protein expression in liver precancerous tissues. Interestingly, EJD significantly reduced YAP and TAZ mRNA expression in the liver precancerous lesions. Collectively, EJD protects against in the initiation of liver cancer and the regulation of c-Myc and Hippo signaling pathways may be the underlying mechanism. Ivyspring International Publisher 2020-10-22 /pmc/articles/PMC7646158/ /pubmed/33193894 http://dx.doi.org/10.7150/jca.49554 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Cheng, Yang
Chen, Tianyang
Chen, Jianjie
Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
title Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
title_full Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
title_fullStr Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
title_full_unstemmed Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
title_short Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
title_sort erzhu jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646158/
https://www.ncbi.nlm.nih.gov/pubmed/33193894
http://dx.doi.org/10.7150/jca.49554
work_keys_str_mv AT chengyang erzhujiedudecoctionamelioratesliverprecancerouslesionsinaratmodeloflivercancer
AT chentianyang erzhujiedudecoctionamelioratesliverprecancerouslesionsinaratmodeloflivercancer
AT chenjianjie erzhujiedudecoctionamelioratesliverprecancerouslesionsinaratmodeloflivercancer